Therapeutics

Developing Next Generation Therapeutics for Healthy Life

Pipeline
Immunology
Product(Partners)
Target
Indication
Region
Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
view more

Batoclimab HBM9161(HanAll)

FcRn

MG*

TED*

NMOSD*

ITP*

CIDP*

PV*

Greater
China

Greater
China

Greater
China

Greater
China

Greater
China

Greater
China

Breakthrough Therapy Designation
view more

Tanfanercept HBM9036(HanAll)

TNFα

Dry Eye Disease

Greater
China

HBM9378

TSLP

Asthma

Global

HBM9022(AbbVie; Utrecht University; Erasmus MC)

SARS-COV-2

COVID-19

Global License to AbbVie

Oncology/Immuno-Oncology
Product(Partners)
Target
Indication
Region
Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
view more

Porustobart HBM4003

CTLA-4

Melanoma, HCC, RCC & Other Advanced Solid Tumors

Melanoma, HCC, NEC/NET & Other Advanced Solid Tumors

NSCLC & Other Advanced Solid Tumors

Global

Global

Global

HBM7008

B7H4x4-1BB

Solid Tumors

Global

HBM7022

Claudin18.2xCD3

Solid Tumors

Global License to AstraZeneca

HBM1022

CCR8

Solid Tumors

Global

view more

HBM1020

B7H7

Solid Tumors

Global

HBM1007

CD73

Solid Tumors

Global

HBM9033

MSLN ADC

Solid Tumors

Global

HBM9027

PD-L1xCD40

Solid Tumors

Global

HBM1047

Undisclosed

Solid Tumors

Global

HBM7004

Undisclosed

Solid Tumors

Global

  • HBM

  • Partner

  • Registrational Clinical Trial

  • Monotherapy

  • PD1 / Chemo

* MG = Myasthenia Gravis

* NMOSD = Neuromyelitis Optica Spectrum Disorder

* ITP = Immune Thrombocytopenic Purpura

* TED = Thyroid Eye Disease

* CIDP = Chronic Inflammatory Demyelinating Polyradiculoneuropathy

* PV = Pemphigus Vulgaris

* HCC = Hepatocellular Carcinoma

* NEN = Neuroendocrine Neoplasms

* NSCLC = Non-Small Cell Lung Cancer

Publications